Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin

Thangirala Sudha, Murat Yalcin, Hung Yun Lin, Ahmed M. Elmetwally, Tipu Nazeer, Thiruvengadam Arumugam, Patricia Phillips, Shaker A. Mousa

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)


Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.

Original languageEnglish
Pages (from-to)25-33
Number of pages9
JournalCancer Letters
Issue number1-2
Publication statusPublished - Aug 1 2014


  • Anti-cancer
  • Low molecular weight heparin
  • Non-anticoagulant heparin
  • Pancreatic cancer
  • Tumor suppressor
  • Tumor survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin'. Together they form a unique fingerprint.

Cite this